Juno Therapeutics

About Juno Therapeutics

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

YEAR FOUNDED:

August 5, 2013

LEADERSHIP:

Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop

JOBS:

Please click here for job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


FOLLOW JUNO:

Tweets by Juno